These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 12503485)

  • 61. [Parallel import of drugs for better and for worse].
    Krabbe U
    Ugeskr Laeger; 2004 Feb; 166(7):611. PubMed ID: 15005051
    [No Abstract]   [Full Text] [Related]  

  • 62. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS
    Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
    [No Abstract]   [Full Text] [Related]  

  • 63. The impact of generic substitution on the turnover and gross margin of pharmaceutical companies a survey 1 year and 5 years after the introduction of generic substitution in Finland.
    Timonen J; Karttunen P; Bengtström M; Ahonen R
    Health Policy; 2009 Oct; 92(2-3):116-23. PubMed ID: 19346023
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Australia amends its free trade deal with US to lessen effect on drug costs.
    Burton B
    BMJ; 2004 Aug; 329(7463):420. PubMed ID: 15321891
    [No Abstract]   [Full Text] [Related]  

  • 65. AIDS drugs. Brazil, Thailand override big pharma patents.
    Cohen J
    Science; 2007 May; 316(5826):816. PubMed ID: 17495145
    [No Abstract]   [Full Text] [Related]  

  • 66. Generic drug stocks: don't get hooked.
    McLean B
    Fortune; 2000 Oct; 142(10):250. PubMed ID: 11184821
    [No Abstract]   [Full Text] [Related]  

  • 67. Meeting in the middle.
    Nature; 2007 Jun; 447(7145):629. PubMed ID: 17554281
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Best buy drugs: many common generics beat brand names.
    Consum Rep; 2011 Mar; 76(3):24-7. PubMed ID: 21434454
    [No Abstract]   [Full Text] [Related]  

  • 69. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Adams J
    N Z Bioeth J; 2003 Oct; 4(3):22-3. PubMed ID: 15597478
    [No Abstract]   [Full Text] [Related]  

  • 70. Reference pricing of pharmaceuticals.
    Brekke KR; Königbauer I; Straume OR
    J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Expensive Medicine: Drug prices are increasingly hard to swallow. Effective remedies prove elusive.
    Bell H
    Minn Med; 2017 May; 100(3):10-17. PubMed ID: 30452131
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Competition body rules that drug companies "abused" their position.
    Sidley P
    BMJ; 2003 Oct; 327(7421):946. PubMed ID: 14576226
    [No Abstract]   [Full Text] [Related]  

  • 73. PBMs' rebate income threatened by lawsuits and move to generics.
    Sipkoff M
    Manag Care; 2008 Mar; 17(3):11-2. PubMed ID: 18447152
    [No Abstract]   [Full Text] [Related]  

  • 74. Drug Regulation and Pricing--Can Regulators Influence Affordability?
    Eichler HG; Hurts H; Broich K; Rasi G
    N Engl J Med; 2016 May; 374(19):1807-9. PubMed ID: 27168431
    [No Abstract]   [Full Text] [Related]  

  • 75. Possible anticompetitive agreements between brand, generic companies to be studied.
    Landis NT
    Am J Health Syst Pharm; 2000 Dec; 57(23):2140, 2142. PubMed ID: 11127691
    [No Abstract]   [Full Text] [Related]  

  • 76. SaskPharm: a proposal for provincial drug production.
    Meili R
    CMAJ; 2011 Jul; 183(10):1224. PubMed ID: 21609991
    [No Abstract]   [Full Text] [Related]  

  • 77. US branded drug makers pay to prevent generic competition.
    Tanne JH
    BMJ; 2008 Jun; 336(7656):1266-7. PubMed ID: 18535046
    [No Abstract]   [Full Text] [Related]  

  • 78. [The war on generic drugs].
    Sternon J
    Rev Med Brux; 2006; 27(5):420-1. PubMed ID: 17176536
    [No Abstract]   [Full Text] [Related]  

  • 79. AstraZeneca must pay €52.5m fine for anticompetitive tactics, rules European court.
    Hawkes N
    BMJ; 2012 Dec; 345():e8396. PubMed ID: 23230222
    [No Abstract]   [Full Text] [Related]  

  • 80. [Access of developing countries to essential drugs: a process of equity].
    Campion MD
    Bull Acad Natl Med; 2001; 185(7):1255-66; discussion 1266-9. PubMed ID: 11975322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.